Adiponectin Ameliorates Iron-Overload Cardiomyopathy through the PPARα–PGC-1α–Dependent Signaling Pathway

Heng Lin, Wei-Shiung Lian, Hsi-Hsien Chen, Pei-Fang Lai, and Ching-Feng Cheng

Department of Medical Research, Tzu Chi General Hospital and Department of Pediatrics, Tzu Chi University, Hualien, Taiwan (W.-S.L., C.-F.C.); Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (W.-S.L., C.-F.C.); Department of Physiology (H.L.), Department of Internal Medicine (H.-H.C.), Division of Nephrology (H.-H.C.), Department of Internal Medicine, College of Medicine, Taipei Medical University Hospital, Taipei, Taiwan; PhD Program in Pharmacology and Toxicology, Tzu Chi University, Hualien, Taiwan (P.-F.L.); and Department of Emergency Medicine, Tzu Chi General Hospital, Hualien, Taiwan (P.-F.L.)

ABSTRACT

Adiponectin is a circulating adipose-derived cytokine that may act as an antioxidative and anti-inflammatory protein. Although adiponectin has been reported to exert cytoprotective effects in acute cardiac diseases, its effects on chronic heart failure are less clear. Therefore, we aimed to investigate whether adiponectin would have a beneficial effect in iron-induced chronic heart failure and to elucidate its regulation in cardiomyocytes. Mice were first treated with iron dextran for 4 weeks to induce iron-overload cardiomyopathy. They exhibited decreased survival with impaired left ventricle contractility and decreased serum adiponectin levels. In vivo cardiac adiponectin gene (ADIPQ) overexpression with adenoassociated virus (AAV)-ADIPQ ameliorated cardiac iron deposition and restored cardiac function in iron-overloaded mice. In addition, AAV-ADIPQ–treated iron-overload mice had lower expression of inflammatory markers, including myeloperoxidase activity, monocye chemotactic protein-1, tumor necrosis factor-α, interleukin-6, and intercellular adhesion molecule-1, than iron-overloaded mice not treated with AAV-ADIPOQ. Our in vitro study showed that adiponectin induced heme oxygenase-1 (HO-1) expression through the peroxisome proliferator-activated receptor (PPARα)–HO-1 signaling pathway. Furthermore, the adiponectin-mediated beneficial effects were PPARα-dependent as the adiponectin-mediated attenuation of iron deposition was abolished in PPARα–knockout mice. Finally, PPARα–HO-1 signaling involved PPARα and peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) binding and nuclear translocation, and their levels were increased by adiponectin therapy. Together, these findings suggest that adiponectin acts as an anti-inflammatory signaling molecule and induces the expression of HO-1 through the PPARα–PGC-1 complex–dependent pathway in cardiomyocytes, resulting in the attenuation of iron-induced cardiomyopathy. Using adiponectin for adjuvant therapies in iron-overload cardiac dysfunction may be an option in the future.

Introduction

Recent advances in adipose biology have provided convincing evidence that adipose tissue can function as an endocrine organ by secreting adipocytokines that influence metabolism in peripheral tissue. Adiponectin is a circulating adipose-derived cytokine that may act as an antioxidative and anti-inflammatory protein and suppress cytokide production in activated macrophages (Zoccali et al., 2002; Cheng et al., 2012; Tian et al., 2012). Previous studies have demonstrated that adiponectin attenuates cardiac hypertrophy in response to pressure overload (Shibata et al., 2004) and reduces atherosclerosis through its vascular anti-inflammatory effects in the cardiovascular system (Hopkins et al., 2007; Hajer et al., 2008; Maury and Brichard, 2010; Vaiopoulos et al., 2012).

Iron can form highly reactive oxygen free radicals, which cause peroxidation of membrane lipids and oxidative damage to cellular proteins (Crowe and Bartfay, 2002), and iron-overload cardiomyopathy is commonly seen in patients who need long-term blood transfusions, such as patients with thalassemia major or hereditary hemochromatosis. Although iron chelation therapy is widely used to treat iron-overload conditions, recent data have shown that iron-overload cardiomyopathy is the primary determinant of cardiac complications and survival in these patients (Fraga and Oteiza, 2002). Lin et al. (2010) demonstrated that adiponectin exerts its protective effects against iron-induced liver injury through...
peroxisome proliferator-activated receptor (PPARα) -dependent heme oxygenase-1 (HO-1) induction. Cheng et al. (2012) demonstrated a similar mechanism in which adiponectin exerts a protective effect against acute renal ischemia-reperfusion (I/R) injury through the prostacyclin-PPARα-HO-1 signaling pathway. These results suggest that adiponectin protects against in vivo tissue inflammation and oxidative stress through PPARα signaling. Recently, Gabrielsen et al. (2012) reported that iron levels in adipocytes can regulate the levels of adiponectin transcription and serum protein and that decreasing tissue iron stores can decrease ferritin and increase adiponectin. They suggested that adipocytes play a role in modulating metabolism and diabetic risks through adiponectin in response to iron stores. However, it is unclear whether adiponectin levels are affected by iron stores in cardiomyocytes, which are commonly observed in patients with iron-overload cardiomyopathy. In addition, since the function of adiponectin gene (ADIPOQ) has not been studied, and the possible involvement of the PPARα-HO-1 signaling pathway is still unclear, we overexpressed ADIPOQ both in vitro and in vivo to test the effect of ADIPOQ overexpression on iron-overload-induced cardiac dysfunction. We also examined whether PPARα and/or peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1α) signaling was involved in regulation of ADIPOQ. We found that adiponectin ameliorated iron deposition in the heart through a PPARα-PGC-1-dependent mechanism and that adiponectin can exert beneficial effects in iron-overload cardiomyopathy.

Materials and Methods

Iron Loading Administration and Serum Enzyme-Linked Immunosorbent Assay Analysis. Male C57/B6, H129 PPARα knockout mice and their wild-type littermates received humane care in compliance with the Principles of Laboratory Animal Care of National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources (National Institutes of Health publication No. 86-23, revised 1985). The study protocol was approved by the institutional ethics committee on animal research. Mice [male, body weight (bw): 25–30 g] were randomly divided into different experimental groups. Iron dextran (Sigma-Aldrich, St. Louis, MO) was i.p. injected to one group at 10 mg/25 g bw per day, 5 days/week for 4 weeks to create an iron-loading group, as previously described (Lian et al., 2011). The mice in the control group were injected with dextrose (0.1 ml of 10%) at the same times over the same period. Mouse sera were harvested for adiponectin, interleukin (IL)-6, monocyte chemoattractant protein (MCP)-1, intercellular adhesion molecule (ICAM)-1, and tumor necrosis factor (TNF)α via enzyme-linked immunosorbent assay (ELISA) kit (Quantikine ELISA; R&D Systems, Wiesbaden, Germany) with reader (450 nm with a correction at 570 nm) used for semiquantification.

Isolation of Cardiomyocytes and Cell Line Culture. Neonatal cardiomyocytes were isolated and cultured according to the method of Fujio et al. (2000) with some modifications. Briefly, the cardiac ventricles of neonatal Wistar rats (male and female, 1–2 days old) were digested with pancreatin (1.25 mg/ml) at 37°C. Cardiomyocytes were isolated and cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 0.1 μM bromodeoxyuridine. After 3 days, cells were incubated in serum-free medium containing transferrin (5 μg/ml), insulin (5 μg/ml), and 0.1 μM bromodeoxyuridine for 24 hours before further treatment with indicated agents. The rat H9c2 cells were acquired from ATCC and were routinely maintained in high glucose Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, penicillin, and streptomycin.

Luciferase Reporter Assay and Chromatin Immunoprecipitation Assay. HO-1 promoter (–1421 to –1400 base pairs (bp)) containing a PPAR response elements (PPRE)–binding sequence were cloned into pGL2-basic vectors (Promega, Madison, WI) and transfected into H9c2 cells. Promoter-induced luciferase activity was measured as described previously (Chen et al., 2008). H9c2 cells were treated with adiponectin and fixed in 1% formaldehyde, and chromatin immunoprecipitation assay was performed following the manufacturer’s protocol (Millipore, Billerica, MA). Chromatin was immune-precipitated with PPARα antibody (1 mg; Santa Cruz Biotechnology, Dallas, TX). Purified DNA was then detected with HO-1 promoter primers by standard polymerase chain reaction.

Preparation of ADIPOQ Recombinant Virus and Protein Production. Full-length cDNA of human ADIPOQ was constructed and transformed into BL-21 Escherichia coli and induced by 1 mM isopropyl β-D-thiogalactopyranoside for 20 hours. Following a standard protocol, adiponectin protein was harvested from E. coli when the optical density (OD)600 of the E. coli broth reached 0.5. Then, NiNTA column and fast protein liquid chromatography gel filtration column (HiLoad 16/60 Superdex 2000; EMBL, Heidelberg, Germany) were added for purification. For adenoassociated virus-ADIPOQ (AAV-ADIPOQ) and adenovirus-ADIPOQ (Adv-ADIPOQ) construction, full-length ADIPOQ cDNA was respectively cloned into the pAAV8-cytomegalovirus (CMV)-multiple cloning sites vector, and a human phosphoglycerate kinase (HPGK) promoter was used to drive ADIPOQ expression. The experimental protocol has been described in detail in prior studies (Lin et al., 2002, 2010). The recombinant AAV-ADIPOQ (with 1 × 1012 viral particles in 50 μl of saline) was injected into a mouse tail vein (i.v.) 2 weeks before the iron treatment. The Adv-HPGK and Adv-ADIPOQ were transduced to cells at different multiplicities of infection (MOI). The recombinant protein of adiponectin, used for in vitro study, was treated to cells in a dose-dependent manner.

Tissue RNA Extraction and Reverse-Transcription Polymerase Chain Reaction. The recombinant AAV-ADIPOQ was injected into a mouse’s tail vein and then tissues from heart, liver, kidney, fat tissue, and muscle were harvested 2 weeks later. Total RNA from individual tissue was extracted by Trizol reagent and homogenized with TissueRuptor (Qiagen, Gaithersburg, MD). The cDNA from 3 μg RNA was used for reverse transcription using a High-Capacity cDNA Reverse Transcription Kit [ABI (Life Technologies), Grand Island, NY]. Quantitative polymerase chain reaction was done using a LightCycler480 (Roche Diagnostics, Mannheim, Germany) and a detection agent PerfeCTa SYBR Green FastMix (Quanta BioSciences, Gaithersburg, MD). Specific primers for ADIPOQ sense, 5′-AAGGGCTCTCAGGATGCTCTGT-3′; and antisense, 5′-AGTAAACGTCTCCTGCGATGA-3′; and PGC-1α sense, 5′-TACCTGACTCGGGTGTATTGGTC-3′; and antisense, 5′-GGTTCTCTTCATAGGACGGCTG-3′; and ICAM-1 sense, 5′-CGCAATCCTAAATCCACTGTA-3′; and antisense, 5′-ATTTCAGAATGCTGCTGAC-3′ were used and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for an internal control. The relative expression ratio of ADIPOQ was calibrated with GAPDH and then compared with control group.

Western Blotting and Immunoprecipitation. The cell pellets were harvested by centrifugation at 250g for 5 minutes at 4°C and were separated into cytoplasmic and nuclear parts using a ProteoJet protein extraction kit [Fermentas (Thermo Fisher Scientific), Rockford, IL]. Protein concentration was determined by Bio-Rad protein assay. Equal amounts of extracted proteins were separated by SDS-PAGE electrophoresis, transferred to polyvinylidene fluoride membranes (Millipore), and probed with primary antibodies; rabbit anti-PGC-1 (1:2000; Santa Cruz Biotechnology), rabbit anti-PPARα (1:1000; Santa Cruz Biotechnology), mouse antiadiponectin (1:1000; Abcam, Cambridge, MA), rabbit antiphosphorylated 5′ adenosine 5′-triphosphate. (b) The diagram depicts the relative expression levels of adiponectin and PPARα in ADIPOQ-overexpressing cells compared to control cells. The expression levels were normalized to GAPDH and presented as fold changes. The error bars represent the mean ± standard deviation of three independent experiments.
monophosphate-activated protein kinase (p-AMPK) (1:1000; Cell Signaling Technology, Danvers, MA), rabbit anti-AMPK (1:1000; Cell Signaling Technology), and rabbit anti-HO-1 (1:1000; Santa Cruz Biotechnology). Mouse antiactin (1:100,000; Abcam), mouse anti-GAPDH (1:3000; Millipore), and rabbit anti-LaminA/C (1:3000; Genetex, Inc., San Antonio, TX) were used as internal controls. For immunoprecipitation (IP), the total cell lysate was prepared by IP lysis buffer [Pierce Biotechnology (ThermoScientific), Rockford, IL] and follow by two to three preclearings with protein A/G agarose to ensure complete removal of endogenous immunoglobulins. The IP/WB Optima C (ImmunoCruz IP/WB Optima F; Santa Cruz Biotechnology) was used for IP antibody/IP matrix formation with the addition of 5 µg of PPARα. Five-hundred micrograms of lysate was then transferred to the specific IP matrix at 4°C on a rotator for overnight rotation. After incubation, the pellet IP matrices were washed and boiled with 2× sample buffer for Western blotting analysis.

Immunohistochemistry for Left Ventricular Tissue. Mouse hearts were perfused through the left ventricle (LV) with 4% paraformaldehyde in 0.1 M phosphate-buffered saline. The paraffin-embedded cardiac cross-sections (5 µm) were stained with iron-specific Prussian blue. Positive stained cells were counted using an image analysis system (Image-Pro Plus v6.0; Media Cybernetics, Inc., Rockville, MD).

Echocardiography Studies. Mice were anesthetized with pentobarbital (50 mg/kg bw i.p.). The anterior chest was shaved and the mouse laid in a left decubitus position. Gel was applied on the chest wall for better scanhead-skin contact. The echocardiography system (Philips HDI 5000) was equipped with 2D, M-mode, and pulse wave Doppler imaging. Heart rate, LV dimension in both systolic and diastolic stages, and the LV fractional shortening/ejection fraction were measured.

Measurement of Biochemical Parameters, Blood Counts, and Myeloperoxidase Activity. Complete blood counts and leukocytes classification were performed using CELL-DYN 3700 (Abbot Diagnostics, Abbott Park, IL). The myeloperoxidase, an indication of neutrophil infiltration into tissue, was measured as previously described (Bradley et al., 1982).

Statistical Analyses. All data are expressed as the means ± S.E.M. or means ± S.D. for blood count test. Survival analysis was performed by Kaplan-Meier method, and between-group differences in survival rates were tested by log-rank test. Between-group comparisons of the means were performed by one-way analysis of variance, followed by t tests. The Bonferroni’s correction was performed for multiple comparisons of the means.

Results

Decreased Serum Adiponectin Levels Were Found in Mice with Iron-Overload Cardiomyopathy. We established mice with iron-overload cardiomyopathy as prior studies (Lian et al., 2011) and these mice showed a decreased survival rate after 4 weeks of iron loading (Fig. 1A). Serum adiponectin levels were significantly lower in mice after 4 weeks of iron supplement compared with the control group (Fig. 1B). These findings suggested that chronic iron loading attenuated serum adiponectin concentrations in vivo.

Cardiac ADIPOQ Overexpression Ameliorated Iron Deposition in the Heart and Restored Normal Cardiac Function. To determine whether ADIPOQ replacement attenuated iron-overload cardiomyopathy, we established a stable and homogenous expression system for ADIPOQ in mouse heart with AAV8, as previously reported (Wang et al., 2005). The expression of ADIPOQ increased significantly in the heart after 2 weeks of i.v. injections of the AAV-ADIPOQ (Fig. 2A). Other organs, including liver, kidney, muscle, and fat tissue, also showed increased levels ADIPOQ expression (Fig. 2B). Consistent with the above results, the serum levels of adiponectin were also markedly increased in the AAV-ADIPOQ experimental group compared with the AAV-CMV–treated control group, likely due to our i.v. infusion of AAV-ADIPOQ with multiple organ expression of ADIPOQ (Fig. 2C). To further investigate the effects of adiponectin on attenuating cardiac iron deposition, we compared sections from the heart tissue in mice that were or were not treated with ADIPOQ following iron loading. ADIPOQ overexpression markedly attenuated iron accumulation in the hearts of mice compared with the control group that was not treated with ADIPOQ (Fig. 2D). In addition, ADIPOQ treatment also restored normal cardiac function by increasing left ventricular fractional shorting and ameliorating left ventricular chamber dilation in iron-loaded hearts compared with the untreated iron-loaded group (Fig. 3A). Together these findings show that
in vivo adiponectin supplementation to the heart minimized/reduced iron-overload–induced cardiomyopathy.

**ADIPOQ Overexpression Suppressed Inflammatory Responses in Iron-Overload Cardiomyopathy.** Because iron loading can induce reactive oxygen species and associated myocardial inflammation, which results in chronic cardiac dysfunction (Bartfay et al., 1999; Oudit et al., 2003), we next investigated whether adiponectin replacement with AAV-ADIPOQ would inhibit iron-induced inflammatory responses in the heart. As seen in Fig. 3B, myocardial myeloperoxidase activity, derived mainly from infiltrated neutrophils, was reduced by one-third (0.68 versus 0.21) in the ADIPOQ-treated group (AAV8-ADIPOQ) compared with the control group (AAV8-CMV). We also examined the cardiac inflammatory profile, including the levels of TNF-α, IL-6, MCP-1, and ICAM-1, by ELISA analysis after 4 weeks of iron loading. The ADIPOQ-treated group showed decreased sera levels of IL-6, MCP-1, and ICAM-1, and a very large reduction (50%) in TNF-α (Fig. 3C), and heart tissue levels of ICAM-1 and TNF-α (Fig. 3D). As can be seen in Table 1, a summary of a complete blood count analysis, lower numbers of leukocytes and lymphocytes were found in the ADIPOQ+ iron-treated group compared with the group treated with iron alone.

**Adiponectin Induced HO-1 Expression in Neonatal Cardiomyocytes through the PPARα–HO-1 Signaling Pathway.** Our previous report demonstrated that adiponectin inhibits renal I/R injury through HO-1 induction (Cheng et al., 2012). Because a PPARα response element, PPRE, is located in the HO-1 promoter region, we examined whether adiponectin exerts its beneficial effects in iron-overload
Fig. 3. ADIPOQ overexpression restored normal left ventricular contraction and ameliorated cardiac inflammation in iron-loading mice. (A) Parameters on echocardiographic results were demonstrated in mice after 4 weeks of iron loading with or without AAV8-ADIPOQ therapy, including heart rates (HR), left ventricular fraction shortening (FS) and ejection fraction (EF); thickness of interventricular septum at diastole (IVSd) and systole (IVSs); and left ventricular internal diameter at diastole (LVIDd), and systole (LVIDs). Values are mean ± S.E.M. (n = 5 per group); *P < 0.05. (B) Myeloperoxidase (MPO) activity of cardiac tissue in iron-loading mice with or without ADIPOQ therapy. MPO activity is expressed as the absorbance at 460 nm/min per milligram protein (n = 8 mice in each group). *P < 0.05. (C) ELISA analysis of MCP-1, IL-6, ICAM-1, and TNF-α levels from sera derived from iron-loading mice with or without ADIPOQ therapy. (D) Quantitative reverse-transcription polymerase chain reaction analysis of TNF-α and ICAM-1 level from heart cDNA derived from iron-loading mice with or without ADIPOQ therapy. Expression levels were normalized to those of GAPDH. Values are mean ± S.E.M. (n = 6 mice in each group). C, control.
cardiomyopathy through this pathway. As seen in Fig. 4A, adiponectin increased the expression of p-AMPK and HO-1. To further examine the interactions between adiponectin and HO-1, and the translocation of PPARα from the cytosol to the nucleus, neonatal cardiomyocytes were infected with adenovirus that contained ADIPOQ or HPGK for assessment of HO-1 induction. Our data showed that HO-1 expression (Fig. 4B) and the PPARα nuclear translocation (Fig. 4C) can be induced by Adv-AADIPOQ in a time-dependent manner (with 100 MOI virus infection). We wanted to investigate whether adiponectin-induced HO-1 expression was dependent on the translocation/binding of PPARα to the PPRE element. We selected a PPAR binding sequence located in the HO-1 promoter (−1421 to −1400 bp) and examined whether the PPARα protein was located in the nucleus and whether it was associated with the PPRE. To do this, we used a chromatin immunoprecipitation assay with both control and adiponectin-stimulated cells at various intervals of incubation (Fig. 4D). Adiponectin-induced association between the PPARα and PPRE region of the HO-1 promoter, with subsequent HO-1 expression, was strongest 0.5 hours after adiponectin treatment followed by gradual attenuation (Fig. 4, A and D). Finally, to determine the activity of adiponectin-induced PPARα binding to the PPRE (HO-1 promoter), we transfected luciferase expression vectors (pGL2) with the HO-1 promoter containing PPRE binding sites in H9c2 cells, and infected with different amounts (50 or 100 MOI) of adenovirus containing either ADIPOQ or HPGK. Increased luciferase activity was found in Adv-AADIPOQ infected with 100 MOI but not 50 MOI (Fig. 4E). Concordantly, we found increased luciferase activity in H9c2 cells treated with 20 μg of adiponectin, but not in those infected with 10 μg (Fig. 4F). These findings suggest that adiponectin might act in a paracrine or autocrine manner to induce HO-1 expression through the PPARα translocation pathway to attenuate iron deposition in the heart.

The Beneficial Effects of Adiponectin-Mediated PPARα–HO-1 in Iron-Overload Cardiac Dysfunction Were PPARα-Dependent. We next examined the adiponectin-mediated PPARα-HO-1 signaling pathway in iron-overloaded mice to determine if the beneficial effects depended on the existence of PPARα, or, more frequently, a redundant function among other PPARs family. To do this, PPARα gene-deleted (PPARα−/−) mice and their wild-type littermates were subjected to 4 weeks of iron loading and ADIPOQ overexpression, as described above. Figure 5 shows that the adiponectin-mediated beneficial effects were completely abolished in the PPARα−/− mice. PPARα−/− mice both with and without ADIPOQ therapy had the same levels of iron deposition in the heart. Surprisingly, higher levels of iron deposition were found in PPARα−/− mice than in the wild-type mice not treated with ADIPOQ. This finding suggests that PPARα, itself, can exert a protective role against iron deposition independent of the adiponectin-mediated pathway, confirming that adiponectin-mediated PPARα–HO-1 beneficial effects against iron-overload cardiac dysfunction were PPARα-dependent.

Involvement of the PGC-1-PPARα Complex in the Nucleus in the Adiponectin-Induced HO-1 Expression. Because the association between the transcriptional coactivator, PGC-1, and PPARα plays important roles in cardiac nutritional and metabolic regulation (Haemmerle et al., 2011), we wondered whether PGC-1 was also involved in the regulation of adiponectin-mediated cardiac protection. As can be seen in Fig. 6A, 24 hours of iron loading in H9c2 cells resulted in a reduction in both cytoplasmic PGC-1 and PPARα levels and a concomitant increase in the levels of nuclear PGC-1 and PPARα. This finding indicated that both PGC-1 and PPARα translocated from cytoplasmic to nuclear fractions during iron-induced stress. Adiponectin supplementation to H9c2 cells increased both the cytoplasmic and nuclear expression of PGC-1 and PPARα, suggesting that adiponectin upregulated cytoplasmic PGC-1 and PPARα signaling, and subsequent nuclear translocation of both components (Fig. 6B). To further confirm the interactions between PPARα and PGC-1 during adiponectin or iron treatment, an immunoprecipitation assay was conducted with H9c2 cells. Figure 6C shows that adiponectin treatment increased the binding between PPARα and PGC-1, and this interaction was reduced by iron-loading, indicating that adiponectin exerted its cytoprotective effects against iron-loading through increased binding between PPARα and PGC-1 and their nuclear translocation.

Discussion

In this study, we first demonstrated decreased serum levels of adiponectin in our mouse model of iron-overload cardiomyopathy. In addition, ADIPOQ overexpression ameliorated cardiac iron deposition and suppressed inflammatory responses, improving left ventricular contraction in iron-overload cardiomyopathy. Moreover, in our in vitro studies showed that the beneficial effects of adiponectin were mediated by the PPARα-dependent HO-1 signaling pathway and required PPARα–PGC-1 interaction. Our study elucidates the cytoprotective effects of adiponectin in iron-induced cardiac dysfunction.

Previous studies have reported that patients with aortic stenosis or diabetes mellitus-induced cardiomyopathy have low circulating levels of adiponectin and high levels of

<table>
<thead>
<tr>
<th>LEUK</th>
<th>ERY</th>
<th>HGB</th>
<th>NEU</th>
<th>LYM</th>
<th>MONO</th>
<th>PLT</th>
</tr>
</thead>
<tbody>
<tr>
<td>× 10^11</td>
<td>× 10^11</td>
<td>g/dl</td>
<td>× 10^9/l</td>
<td>× 10^9/l</td>
<td>× 10^9/l</td>
<td>× 10^9/l</td>
</tr>
<tr>
<td>C</td>
<td>8.9 ± 1.64</td>
<td>9.04 ± 0.27</td>
<td>16.08 ± 0.77</td>
<td>1.75 ± 0.18</td>
<td>6.46 ± 1.47</td>
<td>0.19 ± 0.02</td>
</tr>
<tr>
<td>I</td>
<td>26.67 ± 1.94*</td>
<td>8.26 ± 0.27</td>
<td>15.46 ± 0.32</td>
<td>11.35 ± 0.22**</td>
<td>9.82 ± 1.47*</td>
<td>2.08 ± 0.32*</td>
</tr>
<tr>
<td>I+ADIPOQ</td>
<td>20.93 ± 2.81#</td>
<td>7.04 ± 2.05</td>
<td>14.96 ± 0.69</td>
<td>11.21 ± 2.97</td>
<td>7.45 ± 1.56#</td>
<td>2.05 ± 0.77</td>
</tr>
</tbody>
</table>

ERY, erythrocytes; HGB, hemoglobin; LEUK, leukocytes; LYM, lymphocyte; MONO, monocyte; NEU, neutrophil; PLT, platelet.

* P < 0.05; **P < 0.01 vs. control group (C); #P < 0.05 vs. iron-overload group (I), n = 6–8 in each group.
proinflammatory cytokines (Pischon et al., 2011; Baldasseroni et al., 2012; Won et al., 2012), and one epidemiologic study has found an association between low serum levels of adiponectin and an increased risk of coronary artery disease and severity of coronary artery disease in patients with metabolic syndrome (Kumada et al., 2003). Decreased adiponectin levels have also been reported in animal models of ischemia/reperfusion injury, ventricular hypertrophy, and doxorubicin-induced cardiomyopathy (Shibata et al., 2004, 2005; Wang et al., 2010; Konishi et al., 2011). Furthermore, recent studies have found a negative correlation between the levels of serum ferritin and adiponectin (Forouhi et al., 2007; Mojiminiyi et al., 2008; Ku et al., 2009), suggesting that adipocyte iron negatively regulates ADIPOQ transcription via forkhead box protein O1-mediated repression (Gabrielsen et al., 2012). These findings indicated that increased tissue iron stores are sufficient to increase serum ferritin and decrease serum adiponectin levels. Iron-loading induced oxidative stress with the overexpression of proinflammatory molecules, such as IL-6, MCP-1, TNF-α, and ICAM-1, in heart or blood vasculature (Kahn et al., 2010), which leads to endothelial and cardiac dysfunction. Therefore, it is plausible that decreased levels of adiponectin could be a risk index in cardiac inflammation and associated endothelial dysfunction. In addition, because adiponectin can exert beneficial effects on atheroprotection and anti-inflammation (Hopkins et al., 2007; Zhu et al., 2008), adiponectin is an ideal index, as well as therapy molecule, for cardiovascular diseases.
Previous studies on liver energy regulation have demonstrated that adiponectin has two receptors, which have clearly different signaling pathways. Adiponectin receptor 1 (AdipoR1), which is linked to the activation of the AMPK pathway, regulates the inhibition of liver glucose production and increases in fatty acid oxidation, while adiponectin receptor 2 (AdipoR2) is mainly linked to the activation of the PPARa pathway, which stimulates energy dissipation and inhibits inflammation and oxidative stress. AdipoR1 is abundantly expressed in muscular cells, including cardiomyocytes, whereas AdipoR2 is predominantly expressed in the liver. As adiponectin circulates in serum in either the low-molecular-weight form or the high-molecular-weight (HMW) form, the low-molecular-weight has high binding affinity to AdipoR1 and lower binding affinity with AdipoR2, whereas the HMW has the opposite binding affinity, low to AdipoR1 and high to AdipoR2. Because the overexpressed ADIPOQ that was used in our studies was purified from E. coli, it mostly existed in the HMW form (Cheng et al., 2012). Thus, it binds to AdipoR2 with high affinity and to adipor1 with low affinity. The result of this study suggests that AdipoR2-PPARa signaling might be the major pathway exerting anti-inflammatory and antioxidative stress effects that ameliorate iron-induced cardiac dysfunction. This study also found that these cardioprotective effects were mediated through PPARα signaling, suggesting the existence of cross-talk between AdipoR1/AdipoR2 signaling and the paracrine/autocrine functions of adiponectin in the heart. Recent studies have demonstrated that adiponectin production in the heart can be increased by PPARγ, and the amount of induction is determined by coactivator combination or by the ubiquitination levels of PPARγ or PPARα (Genini and Catapano, 2006).

PPARα, which belongs to the PPAR family, can exhibit anti-inflammatory effects. PPARα agonists or adenoviral-mediated PPARα overexpression in cardiomyocytes can induce the expression of genes involved in fatty acid catabolic pathways, which involve the esterification, binding, transportation, and the β oxidation of fatty acids (Barger et al., 2000; Huss et al., 2001; Gilde et al., 2003). The activation of PPARα has been reported to protect normal or diabetic myocardium against I/R injury through PI3-Kinase/Akt pathway (Bulhak et al., 2009). However, the constant overexpression of PPARα in the heart with cardiac-specific myosin heavy chain (α-MHC) promoter results in increased fatty acid oxidation with decreased glycolysis, which causes left ventricular dysfunction with lipotoxicity (Finck et al., 2002, 2003). These findings support the hypothesis that the beneficial role of PPARα may depend on its coactivators or a different complicated regulation.

PGC-1α, which is the transcriptional coactivator of PPARs, has recently emerged as a key player in the control of myocardial metabolism (Rowe et al., 2010). In cardiac myocytes, the activation of PGC-1α drives a strong induction of PPARα target genes that encode fatty acid oxidation...
enzymes (Lehman et al., 2000). PGC-1α can also coactivate other transcription factors to stimulate mitochondrial biogenesis and enhance the expression of components of the electron transport chain (Lehman et al., 2000; Huss et al., 2002, 2004). One previous study has indicated that adiponectin can inhibit cardiomyocyte apoptosis through the AMPK or adiponectin R1–AMPK–PGC-1 pathway (Konishi et al., 2011), and our data shows that adiponectin can induce the translocation of PPARα that is associated with PGC-1 into the nucleus to inhibit inflammatory responses in iron-loading. Whether the adiponectin-induced beneficial effects of PPARα–PGC-1 on iron-overload cardiac dysfunction come

**Fig. 6.** Adiponectin enhanced PPARα expression and nuclear translocation in association with PGC-1. (A) Expression of PPARα and PGC-1 protein levels in the cytosolic (left upper panel) and nuclear (left lower panel) fractions of the H9c2 cell lines after iron treatment of 24 hours. (B) Adiponectin (APN) supplement–enhanced nuclear translocation of PPARα and PGC-1. Cell lysates from iron-loaded H9c2 cells were treated with or without APN (50 μg) and then separated into nuclear and cytosolic fractions, respectively, and probed with specific antibody against PPARα or PGC-1. Representative results were acquired from two independent experiments. (C) APN can increase PPARα and PGC-1 binding in iron-treated H9c2 cells. H9c2 cells were treated with iron (10 or 20 μM, respectively) and supplied with or without APN for 24 hours; then whole cells lysis were collected for immunoprecipitation with anti-PPARα or anti–PGC-1 antibody followed by immune-blotting (IB) with individual antibody. The antiactin immunoblotting served as sample control. Scanning densitometries in (A), (B), and (C) were used for semiquantitative analysis in comparison with the actin or lamin A/C levels, respectively (right panel); *P < 0.05.
about as a result of PGC-1 induction of increased mitochondrial activity or induction of anti-reactive oxygen species–related gene expression will need to be further evaluated. One recent study by Haemmerle et al. (2011) has reported that hydrolysis of cardiac lipid droplets by adipose triglyceride lipase is required to activate PPAR-mediated PGC-1 expression. This regulation, which specifically occurs in the heart but not in the liver, is PPARα-dependent (but not for PPARγ). Although the exact component of this putative ligand for PPARα is still unknown, our data suggest that PPARα–PGC-1 signaling is essential for maintaining mitochondrial oxidative capacity and ATP generation, which is required for myocardial contractility. In summary, adiponectin has been reported to exert beneficial effects on acute myocardial infarction and I/R injury, and our study further validated the protective role of adiponectin in chronic cardiomyopathy that was induced by iron loading. However, higher adiponectin serum levels are reported to correlate with increased mortality in patients with chronic heart failure (Beatty et al., 2012), thus raising questions about the beneficial role of adiponectin. It is likely that functional adiponectin resistance develops in patients with advanced heart failure with down regulation of adiponectin receptors (Springer et al., 2010; Khan et al., 2012). These findings indicate the importance to clearly delineating the downstream signaling and cross-talk of adiponectin regulation before we can use adiponectin as a future therapeutic regimen for cardiovascular disease. Acknowledgments The authors thank Pei-Chi King for mouse surgery and lability experiments. Authorship Contributions

Participated in research design: Lin, Cheng.
Conducted data analysis: Lin, Lian, Cheng.
Wrote or contributed to the writing of the manuscript: Lin, Lian, Cheng.

References
Bartfay WJ, Butany J, Lehotay DC, Sole MJ, Hou D, Bartfay E, and Liu PP (1999) A novel mechanism for nuclear iron uptake and retention in the liver, is PPARα-dependent, but not in the liver, is PPARα-dependent, but not for PPARγ. Although the exact component of this putative ligand for PPARα is still unknown, our data suggest that PPARα–PGC-1 signaling is essential for maintaining mitochondrial oxidative capacity and ATP generation, which is required for myocardial contractility. In summary, adiponectin has been reported to exert beneficial effects on acute myocardial infarction and I/R injury, and our study further validated the protective role of adiponectin in chronic cardiomyopathy that was induced by iron loading. However, higher adiponectin serum levels are reported to correlate with increased mortality in patients with chronic heart failure (Beatty et al., 2012), thus raising questions about the beneficial role of adiponectin. It is likely that functional adiponectin resistance develops in patients with advanced heart failure with down regulation of adiponectin receptors (Springer et al., 2010; Khan et al., 2012). These findings indicate the importance to clearly delineating the downstream signaling and cross-talk of adiponectin regulation before we can use adiponectin as a future therapeutic regimen for cardiovascular disease. Acknowledgments The authors thank Pei-Chi King for mouse surgery and lability experiments. Authorship Contributions

Participated in research design: Lin, Cheng.
Conducted data analysis: Lin, Lian, Cheng.
Wrote or contributed to the writing of the manuscript: Lin, Lian, Cheng.


Address correspondence to: Dr. Ching-Feng Cheng, Department of Medical Research, Tzu Chi General Hospital and Department of Pediatrics, Tzu Chi University, Hualien, 707, Chung-Yang Road, Section 3, Hualien City, Taiwan. E-mail: chengcf@mail.tcu.edu.tw